TOOLS AND RESOURCES
HEAR FROM EXPERTS ABOUT THE DAMAGE THAT MAY BE CAUSED BY LARGELY UNADDRESSED INFLAMMATION AND FIBROSIS IN PATIENTS WITH CKD AND T2D1-6
Rajiv Agarwal, MD, takes us through how MR overactivation impacts inflammation and fibrosis and leads to CKD progression
Peter Rossing, MD, discusses the burden that CKD presents for patients with T2D
Peter Rossing, MD, helps us understand the daily management needs of those living with CKD and T2D
This video explains the mode of disease behind CKD in patients with T2D
Hear from patients around the world about their experiences living with CKD and T2D
CKD: chronic kidney disease; MR: mineralocorticoid receptor; T2D: type 2 diabetes; UACR: urine albumin-to-creatinine ratio.
References:
- Tesch GH, et al. Front Pharmacol. 2017;8. doi:10.3389/fphar.2017.00313. Return to content
- Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
- Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
- Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
- Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content
- ACR. National Kidney Foundation. Accessed January 12, 2021. https://www.kidney.org/kidneydisease/siemens_hcp_acr. Return to content
- Campion CG, et al. Can J Kidney Health Dis. 2017;4. doi:10.1177/2054358117705371. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1–150. Return to content